Search

Patterson, M E, P Marken, Y Zhong, S D Simon, and W Ketcherside. 2014. “Comprehensive Electronic Medical Record Implementation Levels Not Associated With 30-Day All-Cause Readmissions Within Medicare Beneficiaries With Heart Failure.”. Applied Clinical Informatics 5 (3): 670-84.

Patterson, M E, P A Marken, S D Simon, J L Hackman, and R S Schaefer. 2012. “Associations Between the Concurrent Use of Clinical Decision Support and Computerized Provider Order Entry and the Rates of Appropriate Prescribing at Discharge.”. Applied Clinical Informatics 3 (2): 186-96.

Patterson, Mark E, Adrian F Hernandez, Bradley G Hammill, Gregg C Fonarow, Eric D Peterson, Kevin A Schulman, and Lesley H Curtis. 2010. “Process of Care Performance Measures and Long-Term Outcomes in Patients Hospitalized With Heart Failure.”. Medical Care 48 (3): 210-6.

Patterson, Mark E, Sandra Bollinger, Chandler Coleman, and James A M Rhodes. 2022. “Medication Discrepancy Rates and Sources Upon Nursing Home Intake: A Prospective Study.”. Research in Social & Administrative Pharmacy : RSAP 18 (5): 2830-36.

Louiselle, Katie, Lory Harte, Charity Thompson, Damon Pabst, Andrea Calvert, and Mark E Patterson. 2021. “Medication Discrepancy Risk Factors for Pediatric Patients With Epilepsy at Hospital Admission.”. The Journal of Pediatric Pharmacology and Therapeutics : JPPT : The Official Journal of PPAG 26 (4): 384-94.

Patterson, Mark E, and Dakota J Rosenfelt. 2018. “Justifying High Drug Prices Within the Context of Value: Biologics versus Generics.”. Research in Social & Administrative Pharmacy : RSAP 14 (2): 121-23.

Thorpe, Joshua M, Carolyn T Kalinowski, Mark E Patterson, and Betsy L Sleath. 2006. “Psychological Distress As a Barrier to Preventive Care in Community-Dwelling Elderly in the United States.”. Medical Care 44 (2): 187-91.

Lewellyan, Colleen M, Patrick Spoutz, Monica Schaefer, and Mark E Patterson. 2022. “Risk of Volume Depletion Events With Concomitant Use of Sodium Glucose Co-Transporter 2 Inhibitors and Loop Diuretics: A Self-Controlled Case Series Study.”. Pharmacoepidemiology and Drug Safety 31 (10): 1102-9.